• Gilead issues a press release summarizing initial findings from the remdesivir phase III SIMPLE trial in people with moderate COVID-19 (hospitalized, with pneumonia – but not reduced oxygen levels). The trial compared a 5-or 10-day course of remdesivir to standard of care, with a clinical status (ranging from hospital discharge to death) at Day 11 as the primary endpoint; adverse event rates are the secondary endpoint. The press release reported that higher proportion of people in the 5-day treatment arm had improved clinical status versus those given standard of care. Source
• Russia’s Ministry of Health approves Avifavir (favipiravir) for COVID-19. Source
